Atox Bio develops therapeutics for diseases mediated by an excessive inflammatory response. Atox Bio focuses on novel modulators of co-stimulation that act broadly to attenuate the excessive cytokine responses that underlie disease in two primary therapeutic areas: infectious diseases (including severe sepsis, swine/avian influenza) and inflammatory diseases. Over $12 million dollars were granted for research by the US Army, DARPA, and NIAID which assigned top ratings to Atox Bio in peer review. The research was selected by DARPA for presentation to the White House.

Atox Bio plans to advance AB103, the company’s lead product, into human proof of concept trials, targeting sepsis, Gram-positive infections, and influenza.

Upon successful completion of the first human proof of concept trials, Atox Bio plans on collaborating with a pharmaceutical company for further clinical development and product commercialization.

The company also plans to advance its pipeline of pre-clinical candidates for inflammatory and autoimmune diseases, and partner them once human safety has been established.

Technology

Atox Bio’s scientists have elucidated a novel mechanism involved in harmful inflammatory cytokine responses. This allowed for the design of antagonists that block symptoms of disease in inflammatory as well as Gram+ and Gram- sepsis models, and shows synergy with Tamiflu in protecting mice from the lethal avian influenza infection.

This unique technology eventually generated AB103, Atox Bio’s lead product that will begin clinical trials in Q2/2010.

Other candidates are being optimized and developed for inflammatory and autoimmune diseases, including MS, uveitis, acute GvHD and lupus.

Contact Details
Address: 10 Menahem Plaut St., Rehovot, 76706
Phone: +972-8-938-0901
Fax : +972-153-8-938-0901
Email: dant@atoxbio.com            
Internet Site: www.atoxbio.com 

Exhibition Representative
Name: Dan Teleman
Mobile: +972-54-550-0804
E-mail: dant@atoxbio.com 

Catagory: Biotechnology